Global Breast Cancer Predictive Genetic Testing Market Outlook 2022
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
“Global Breast Cancer Predictive Genetic Testing Market Outlook 2022” report analyzes the various aspects related to the emergence and development of breast cancer genetic test market across the globe. Currently the market is more predominantly developed in US and Europe. The increasing awareness and favorable regulatory pathways has led to
The current and future aspects of cancer genomics have covered a long path of advances and the journey is still ongoing. The technological improvements in genomic sciences had allowed parallel sequencing of both tumors and germline mutations and had provided the weapon of next generation sequencing. Under the supervision of intellectual property laws and appropriate guidelines cancer susceptibility testing has become one of the major assets in medical practice. There appears to be pervasive belief in both scientific and public circles that genetic testing is going to be the cornerstone of much, if not all, of what medicine holds for the future. Besides, what is generally meant is the wide scale testing for susceptibility to common diseases especially for cancer and for responsiveness to drugs has come to be described as genetic profiling.
With the knowledge and acceptance of the fact that the breast cancer is on alarming scale, the major concern has been diverted towards this scenario. As there are 5% to 10% of breasts cancer cases which occur due to the germline mutations and the most common ones are the BRCA1 and BRCA2 mutations. Fortunately, these hereditary cancers can be prevented if diagnosed early or even before its occurrence which includes the susceptibility testing of breast cancer genes.
Breast cancer susceptibility has been in existence since 1966 and had served as the boon for the patients as well as the stakeholders. Certainly, 2013 have been the year of major events in the field of predictive genetic testing as US FDA approved the use of next generation DNA sequencing in clinical practice. Further, the decision of Supreme Court invalidated the BRCA patent held by Myriad genetics. These decisions made the new entries and embraced the competitions in the cancer genetics market.
Leading to the current scenario which is completely changing and the market is now subjected to the direct to consumer BRCA testing kits provided by varied pharmaceuticals. However, the new entrants to the global market will face considerable challenges in persuading physicians to choose them as a test provider. New entrants will need to provide indication of subsequent in meeting the requirements of physicians such as reputation, trust, transparency, and counseling. Some of these aspects cannot be established quickly, and take time to establish.
The future holds up for the precision medicine and cancer predictability will be proving a great deal, as through the aid of breast cancer predictive testing and better counseling measures this regimen can turn out into an effective prophylactic modality for hereditary as well as early stage breast cancer. The predictive risk calculations will be leading towards the better management and improved survival rates. Over the next decade or two, it seems likely that the technology will screen entire populations or specific subgroups for genetic information in order to target interventions to individual patients that will improve their health and prevent disease. While the evidence base is still growing, genetic services industry leaders strongly believe that emerging testing capabilities will have significant clinical impact in the future.
“Global Breast Cancer Predictive Genetic Testing Market Outlook 2022” Report Highlights:
“Global Breast Cancer Predictive Genetic Testing Market Outlook 2022” report analyzes the various aspects related to the emergence and development of breast cancer genetic test market across the globe. Currently the market is more predominantly developed in US and Europe. The increasing awareness and favorable regulatory pathways has led to
The current and future aspects of cancer genomics have covered a long path of advances and the journey is still ongoing. The technological improvements in genomic sciences had allowed parallel sequencing of both tumors and germline mutations and had provided the weapon of next generation sequencing. Under the supervision of intellectual property laws and appropriate guidelines cancer susceptibility testing has become one of the major assets in medical practice. There appears to be pervasive belief in both scientific and public circles that genetic testing is going to be the cornerstone of much, if not all, of what medicine holds for the future. Besides, what is generally meant is the wide scale testing for susceptibility to common diseases especially for cancer and for responsiveness to drugs has come to be described as genetic profiling.
With the knowledge and acceptance of the fact that the breast cancer is on alarming scale, the major concern has been diverted towards this scenario. As there are 5% to 10% of breasts cancer cases which occur due to the germline mutations and the most common ones are the BRCA1 and BRCA2 mutations. Fortunately, these hereditary cancers can be prevented if diagnosed early or even before its occurrence which includes the susceptibility testing of breast cancer genes.
Breast cancer susceptibility has been in existence since 1966 and had served as the boon for the patients as well as the stakeholders. Certainly, 2013 have been the year of major events in the field of predictive genetic testing as US FDA approved the use of next generation DNA sequencing in clinical practice. Further, the decision of Supreme Court invalidated the BRCA patent held by Myriad genetics. These decisions made the new entries and embraced the competitions in the cancer genetics market.
Leading to the current scenario which is completely changing and the market is now subjected to the direct to consumer BRCA testing kits provided by varied pharmaceuticals. However, the new entrants to the global market will face considerable challenges in persuading physicians to choose them as a test provider. New entrants will need to provide indication of subsequent in meeting the requirements of physicians such as reputation, trust, transparency, and counseling. Some of these aspects cannot be established quickly, and take time to establish.
The future holds up for the precision medicine and cancer predictability will be proving a great deal, as through the aid of breast cancer predictive testing and better counseling measures this regimen can turn out into an effective prophylactic modality for hereditary as well as early stage breast cancer. The predictive risk calculations will be leading towards the better management and improved survival rates. Over the next decade or two, it seems likely that the technology will screen entire populations or specific subgroups for genetic information in order to target interventions to individual patients that will improve their health and prevent disease. While the evidence base is still growing, genetic services industry leaders strongly believe that emerging testing capabilities will have significant clinical impact in the future.
“Global Breast Cancer Predictive Genetic Testing Market Outlook 2022” Report Highlights:
- Hereditary Breast Cancer Genes
- Conceptual of Breast Cancer Susceptibility
- Predictive Cancer Testing Essentials
- Economical, Ethical & Social Aspects
- Global Prevalence of Breast Cancer
- Market & Cost Analysis of Predictive Testing
- Insurance Affairs for Breast Cancer Predictive Testing
1. CANCER SUSCEPTIBILITY TESTING
1.1 Prologue to Cancer Susceptibility
1.2 Aspects of Cancer Susceptibility Testing
2. BREAST CANCER SUSCEPTIBILITY
2.1 Conceptual of Breast Cancer Susceptibility
2.2 Trail of the Inherited Susceptible Genes
3. HEREDITARY BREAST CANCER GENES
3.1 High Penetrant Genes
3.1.1 Breast Cancer Gene1 (BRCA1)
3.1.2 Breast Cancer Gene 2 (BRCA2)
3.1.3 TP53
3.1.4 PTEN
3.1.5 STK11 & CDH1
3.2 Intermediate Penetrant Genes
3.2.1 CHEK2
3.2.2 PALB2
3.2.3 ATM
3.2.4 Other Genes
3.3 Low Penetrant Genes
4. BREAST CANCER SUSCEPTIBLE SYNDROMES
4.1 Hereditary Breast & Ovarian Cancer
4.2 Cowden Syndrome
4.3 Li-Fraumeni Syndrome
4.4 Peutz-Jeghers Syndrome
5. CANCER SUSCEPTIBILITY TESTING ESSENTIALS
5.1 Prerequisites towards Cancer Susceptibility
5.2 Sequential Stages in Testing
6. GENETIC CANCER SUSCEPTIBILITY TESTING
6.1 Risk Assessment
6.2 Genetic Counseling
6.3 Genetic Testing
6.4 Post-Test Counseling
7. MANAGEMENT OF HEREDITARY RISK
7.1 Surveillance
7.2 Chemoprevention
7.3 Bilateral Prophylactic Mastectomy
8. ECONOMICAL, ETHICAL & SOCIAL ASPECTS
8.1 Economic Aspects of Cancer Susceptibility Testing
8.2 Ethical Aspects of Cancer Susceptibility Testing
8.3 Social Aspects of Cancer Susceptibility Testing
9. GLOBAL PREVALENCE OF BREAST CANCER
9.1 Breast Cancer Incidences
9.2 Germline Breast Cancer Ethnicity
10. PREVALENCE OVER GEOGRAPHIC REGIONS
10.1 Prevalence in Developed Regions
10.1.1 US
10.1.2 Europe
10.1.3 Canada
10.1.4 Japan
10.2 Prevalence in Developing Regions
10.2.1 China
10.2.2 India
10.2.3 Africa
11. PREFACE OF MONETARY PROSPECTS
11.1 Cost of Breast Cancer Susceptibility Testing
11.2 Insurance Affairs for Breast Cancer Susceptibility Testing
12. ASPECTS OF CANCER SUSCEPTIBILITY MARKET
12.1 Breast Cancer Susceptibility Market Overview
12.2 Direct To Consumer Market
13. GLOBAL BREAST CANCER PREDICTIVE GENETIC TESTING MARKET DYNAMICS
13.1 Accelerative Parameters
13.2 Challenges
14. GLOBAL BREAST CANCER PREDICTIVE GENETIC TESTING MARKET FUTURE ASPECTS
15. COMPETITIVE LANDSCAPE
15.1 Cancer Genetics
15.2 Invitae
15.3 Iverson Genetics
15.4 Myriad Genetics
15.5 NeoGenomics
15.6 Oncocyte
15.7 PerkinElmer
15.8 Quest Diagnostics
15.9 Roche
15.10 Thermo Fisher Scientific
1.1 Prologue to Cancer Susceptibility
1.2 Aspects of Cancer Susceptibility Testing
2. BREAST CANCER SUSCEPTIBILITY
2.1 Conceptual of Breast Cancer Susceptibility
2.2 Trail of the Inherited Susceptible Genes
3. HEREDITARY BREAST CANCER GENES
3.1 High Penetrant Genes
3.1.1 Breast Cancer Gene1 (BRCA1)
3.1.2 Breast Cancer Gene 2 (BRCA2)
3.1.3 TP53
3.1.4 PTEN
3.1.5 STK11 & CDH1
3.2 Intermediate Penetrant Genes
3.2.1 CHEK2
3.2.2 PALB2
3.2.3 ATM
3.2.4 Other Genes
3.3 Low Penetrant Genes
4. BREAST CANCER SUSCEPTIBLE SYNDROMES
4.1 Hereditary Breast & Ovarian Cancer
4.2 Cowden Syndrome
4.3 Li-Fraumeni Syndrome
4.4 Peutz-Jeghers Syndrome
5. CANCER SUSCEPTIBILITY TESTING ESSENTIALS
5.1 Prerequisites towards Cancer Susceptibility
5.2 Sequential Stages in Testing
6. GENETIC CANCER SUSCEPTIBILITY TESTING
6.1 Risk Assessment
6.2 Genetic Counseling
6.3 Genetic Testing
6.4 Post-Test Counseling
7. MANAGEMENT OF HEREDITARY RISK
7.1 Surveillance
7.2 Chemoprevention
7.3 Bilateral Prophylactic Mastectomy
8. ECONOMICAL, ETHICAL & SOCIAL ASPECTS
8.1 Economic Aspects of Cancer Susceptibility Testing
8.2 Ethical Aspects of Cancer Susceptibility Testing
8.3 Social Aspects of Cancer Susceptibility Testing
9. GLOBAL PREVALENCE OF BREAST CANCER
9.1 Breast Cancer Incidences
9.2 Germline Breast Cancer Ethnicity
10. PREVALENCE OVER GEOGRAPHIC REGIONS
10.1 Prevalence in Developed Regions
10.1.1 US
10.1.2 Europe
10.1.3 Canada
10.1.4 Japan
10.2 Prevalence in Developing Regions
10.2.1 China
10.2.2 India
10.2.3 Africa
11. PREFACE OF MONETARY PROSPECTS
11.1 Cost of Breast Cancer Susceptibility Testing
11.2 Insurance Affairs for Breast Cancer Susceptibility Testing
12. ASPECTS OF CANCER SUSCEPTIBILITY MARKET
12.1 Breast Cancer Susceptibility Market Overview
12.2 Direct To Consumer Market
13. GLOBAL BREAST CANCER PREDICTIVE GENETIC TESTING MARKET DYNAMICS
13.1 Accelerative Parameters
13.2 Challenges
14. GLOBAL BREAST CANCER PREDICTIVE GENETIC TESTING MARKET FUTURE ASPECTS
15. COMPETITIVE LANDSCAPE
15.1 Cancer Genetics
15.2 Invitae
15.3 Iverson Genetics
15.4 Myriad Genetics
15.5 NeoGenomics
15.6 Oncocyte
15.7 PerkinElmer
15.8 Quest Diagnostics
15.9 Roche
15.10 Thermo Fisher Scientific
LIST OF FIGURES
Figure 1-1: Layout of Traditional & Advanced Cancer Susceptibility Testing
Figure 2-1: Demonstration of the Potentials Aspects of the Cancer Susceptibility Testing
Figure 3-1: Common Genetic Variants of Breast Cancer Susceptible Genes
Figure 3-2: Percentage of BRCA1 Gene Mutations & Other Genes for Breast Cancer
Figure 3-3: Breast Cancer Risk by Carriers & Non-Carriers with Growing Age
Figure 3-4: Representation of Gene Specific Lifetime Breast Cancer Risks
Figure 3-5: Percentage of Risk Factors of Breast Cancer & Variability of Penetrance Genes
Figure 4-1: Percentage Share of the Causes of Breast Cancer Risk Assessment
Figure 4-2: Number of Genes Associated With Hereditary Breast Cancer Syndrome
Figure 4-3: The Cumulative Lifetime Risk to Age 70 Years for Breast or Ovarian Cancer
Figure 4-4: Li-Fraumani Syndrome Age Related Risk Patterns for Cancer Development
Figure 5-1: Advantages of Genetic Cancer Susceptibility Tests
Figure 5-2: The Criteria of Target Population for Genetic Testing of Breast Cancer
Figure 5-3: Representation of the Sequential Stages in the Cancer Susceptibility Testing
Figure 6-1: The Concept of Breast Cancer Risk Assessment & Management
Figure 6-2: The Outline of Genetic Test for Breast Cancer Susceptibility
Figure 6-3: Interpretation of Possible Outcomes after Cancer Genetic Testing
Figure 7-1: Management Strategies of Hereditary Risk of Breast Cancer
Figure 7-2: Percentage of Cancer Risk Reductions via Varied Management Strategies
Figure 8-1: Proportion of Cost Effectiveness Ratios in Predictive Genetic Test
Figure 8-2: Ethical Issues of Breast Cancer Susceptibility Testing
Figure 9-1: Global - Demonstration of Incidence & Mortality Rate of Breast Cancer
Figure 9-2: Global - Comparative Percentage of Risk of Developing Breast Cancer in Women
Figure 9-3: US - Prevalence of BRCA Mutation Percentage among White Population
Figure 9-4: UK - Prevalence of BRCA Mutations Percentage among White Population
Figure 9-5: Prevalence of Mutations in Ashkenazi Jewish Individuals
Figure 10-1: US - Rates of Incidence and Mortality Breast Cancer in US as per 100,000
Figure 10-2: US- Prevalence of BRCA1 Mutations Percentage over the Base of Ethnicity
Figure 10-3: Europe - Percentage of Incidence & Mortality of Breast Cancer
Figure 10-4: UK - Rate of Breast Cancer Incidence Related to Age, 2014
Figure 10-5: Europe - Percentage of BRCA1 Mutation in High Risk Families
Figure 10-6: Canada - Percentage of All New Cancer Cases & Breast Cancer Cases, 2016
Figure 10-7: Canada - Percentage of New Breast Cancer Diagnosed in Canadian Women by Age Group, 2016
Figure 10-8: Japan - Incidence Rates of Breast Cancer as per 100,000
Figure 10-9: China - Incidence & Mortality Rates in Chinese Population, 2015
Figure 10-10: India - Percentage of Increasing Incidence of Breast Cancer in Younger Age Groups
Figure 10-11: Central Africa - Age Adjusted Incidence & Death Rates for Breast Cancer
Figure 11-1: US - Cost of Breast Cancer Susceptibility Testing (US$)
Figure 11-2: UK - Cost of Breast Cancer Susceptibility Testing (US$)
Figure 11-3: Canada - Cost Range of Breast Cancer Susceptibility Testing (US$)
Figure 11-4: Japan - Cost Range of Breast Cancer Susceptibility Testing (US$)
Figure 11-5: Australia & New Zealand - Cost of Breast Cancer Susceptibility Testing (US$)
Figure 11-6: China - Cost of Breast Cancer Susceptibility Testing in China (US$)
Figure 11-7: India - Cost of Breast Cancer Susceptibility Testing (US$)
Figure 11-8: Singapore - Cost of BRCA Testing & Mastectomy
Figure 12-1: Myriad’s - Market Sales for BRCA Testing (US$ Millions)
Figure 12-2: Criticism for the BRCA Testing Genes Patented by Myriad Genetics
Figure 12-3: The Cost Comparison of Myriads BRCA Testing & Other Competitors (US$)
Figure 12-4: Price Difference between Healthcare BRCA Testing & Direct to Consumer Test
Figure 12-5: Global – BRCA Susceptibility Testing Market Opportunity (US$ Million), 2017-2022
Figure 12-6: US – BRCA Susceptibility Testing Market Opportunity (US$ Million), 2017-2022
Figure 12-7: Europe – BRCA Susceptibility Testing Market Opportunity (US$ Million), 2017-2022
Figure 12-8: Asia – BRCA Susceptibility Testing Market Opportunity (US$ Million), 2017-2022
Figure 13-1: Global - Major Parameters of Growth in Breast Cancer Susceptibility Testing
Figure 13-2: Global - Major Challenges of Breast Cancer Susceptibility Market
Figure 1-1: Layout of Traditional & Advanced Cancer Susceptibility Testing
Figure 2-1: Demonstration of the Potentials Aspects of the Cancer Susceptibility Testing
Figure 3-1: Common Genetic Variants of Breast Cancer Susceptible Genes
Figure 3-2: Percentage of BRCA1 Gene Mutations & Other Genes for Breast Cancer
Figure 3-3: Breast Cancer Risk by Carriers & Non-Carriers with Growing Age
Figure 3-4: Representation of Gene Specific Lifetime Breast Cancer Risks
Figure 3-5: Percentage of Risk Factors of Breast Cancer & Variability of Penetrance Genes
Figure 4-1: Percentage Share of the Causes of Breast Cancer Risk Assessment
Figure 4-2: Number of Genes Associated With Hereditary Breast Cancer Syndrome
Figure 4-3: The Cumulative Lifetime Risk to Age 70 Years for Breast or Ovarian Cancer
Figure 4-4: Li-Fraumani Syndrome Age Related Risk Patterns for Cancer Development
Figure 5-1: Advantages of Genetic Cancer Susceptibility Tests
Figure 5-2: The Criteria of Target Population for Genetic Testing of Breast Cancer
Figure 5-3: Representation of the Sequential Stages in the Cancer Susceptibility Testing
Figure 6-1: The Concept of Breast Cancer Risk Assessment & Management
Figure 6-2: The Outline of Genetic Test for Breast Cancer Susceptibility
Figure 6-3: Interpretation of Possible Outcomes after Cancer Genetic Testing
Figure 7-1: Management Strategies of Hereditary Risk of Breast Cancer
Figure 7-2: Percentage of Cancer Risk Reductions via Varied Management Strategies
Figure 8-1: Proportion of Cost Effectiveness Ratios in Predictive Genetic Test
Figure 8-2: Ethical Issues of Breast Cancer Susceptibility Testing
Figure 9-1: Global - Demonstration of Incidence & Mortality Rate of Breast Cancer
Figure 9-2: Global - Comparative Percentage of Risk of Developing Breast Cancer in Women
Figure 9-3: US - Prevalence of BRCA Mutation Percentage among White Population
Figure 9-4: UK - Prevalence of BRCA Mutations Percentage among White Population
Figure 9-5: Prevalence of Mutations in Ashkenazi Jewish Individuals
Figure 10-1: US - Rates of Incidence and Mortality Breast Cancer in US as per 100,000
Figure 10-2: US- Prevalence of BRCA1 Mutations Percentage over the Base of Ethnicity
Figure 10-3: Europe - Percentage of Incidence & Mortality of Breast Cancer
Figure 10-4: UK - Rate of Breast Cancer Incidence Related to Age, 2014
Figure 10-5: Europe - Percentage of BRCA1 Mutation in High Risk Families
Figure 10-6: Canada - Percentage of All New Cancer Cases & Breast Cancer Cases, 2016
Figure 10-7: Canada - Percentage of New Breast Cancer Diagnosed in Canadian Women by Age Group, 2016
Figure 10-8: Japan - Incidence Rates of Breast Cancer as per 100,000
Figure 10-9: China - Incidence & Mortality Rates in Chinese Population, 2015
Figure 10-10: India - Percentage of Increasing Incidence of Breast Cancer in Younger Age Groups
Figure 10-11: Central Africa - Age Adjusted Incidence & Death Rates for Breast Cancer
Figure 11-1: US - Cost of Breast Cancer Susceptibility Testing (US$)
Figure 11-2: UK - Cost of Breast Cancer Susceptibility Testing (US$)
Figure 11-3: Canada - Cost Range of Breast Cancer Susceptibility Testing (US$)
Figure 11-4: Japan - Cost Range of Breast Cancer Susceptibility Testing (US$)
Figure 11-5: Australia & New Zealand - Cost of Breast Cancer Susceptibility Testing (US$)
Figure 11-6: China - Cost of Breast Cancer Susceptibility Testing in China (US$)
Figure 11-7: India - Cost of Breast Cancer Susceptibility Testing (US$)
Figure 11-8: Singapore - Cost of BRCA Testing & Mastectomy
Figure 12-1: Myriad’s - Market Sales for BRCA Testing (US$ Millions)
Figure 12-2: Criticism for the BRCA Testing Genes Patented by Myriad Genetics
Figure 12-3: The Cost Comparison of Myriads BRCA Testing & Other Competitors (US$)
Figure 12-4: Price Difference between Healthcare BRCA Testing & Direct to Consumer Test
Figure 12-5: Global – BRCA Susceptibility Testing Market Opportunity (US$ Million), 2017-2022
Figure 12-6: US – BRCA Susceptibility Testing Market Opportunity (US$ Million), 2017-2022
Figure 12-7: Europe – BRCA Susceptibility Testing Market Opportunity (US$ Million), 2017-2022
Figure 12-8: Asia – BRCA Susceptibility Testing Market Opportunity (US$ Million), 2017-2022
Figure 13-1: Global - Major Parameters of Growth in Breast Cancer Susceptibility Testing
Figure 13-2: Global - Major Challenges of Breast Cancer Susceptibility Market
LIST OF TABLES
Table 4-1: High Penetrance Mutation Variants Corresponding to Breast Cancer Syndromes
Table 7-1: Schedule of Surveillance of Breast Cancer According To Age
COMPANIES MENTIONED
Cancer Genetics
Invitae
Iverson Genetics
Myriad Genetics
NeoGenomics
Oncocyte
PerkinElmer
Quest Diagnostics
Roche
Thermo Fisher Scientific
Table 4-1: High Penetrance Mutation Variants Corresponding to Breast Cancer Syndromes
Table 7-1: Schedule of Surveillance of Breast Cancer According To Age
COMPANIES MENTIONED
Cancer Genetics
Invitae
Iverson Genetics
Myriad Genetics
NeoGenomics
Oncocyte
PerkinElmer
Quest Diagnostics
Roche
Thermo Fisher Scientific
